专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5035878A Use of dithiocarbamates to counteract myelosuppression 失效
标题翻译：使用二硫代氨基甲酸盐来抵抗骨髓抑制
公开(公告)号：US5035878A
公开(公告)日：1991-07-30
申请号：US418549
申请日：1989-10-10
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27 , A61K38/00 , C07K14/53 , C12N5/077
CPC分类号： C12N5/0669 , A61K31/27 , C07K14/53 , A61K38/00 , C12N2501/999 , Y10S514/823 , Y10S514/885 , Y10S514/922
摘要： Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R.sub.1 R.sub.2 NCSSM or R.sub.1 R.sub.2 NCSS-SCSNR.sup.3 R.sup.4, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 can be H, or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g.
摘要翻译：各种类型的生物处理，包括抗肿瘤药物的抗肿瘤治疗可能会损害骨髓的血液形成功能。至少在某种程度上可以使用有效量（优选极低剂量）的药学上可接受的二硫代氨基甲酸酯化合物，包括式R1R2NCSSM或R1R2NCSS-SCSNR3R4的化合物，其中R 1，R 2，R 3和 R4是相同或不同的未取代或被羟基取代的脂族或脂环族或杂脂肪族基团，或R 1和R 2之一，R 3和R 4中的一个可以是H，或者R 1和R 2或R 3和R 4与N原子一起一对R基团被取代的基团可以是被环氧或第二环氮中断的脂族或脂族的5-或6-元N-杂环，M是H或一当量的药学上可接受的阳离子在这种情况下，分子的其余部分是带负电荷的。哺乳动物的剂量可以为约0.001至30mg / kg体重。对于较大的哺乳动物，包括人类，典型的剂量单位小于10mg / kg，例如 <3 mg / kg。剂量单位可以溶解在合适的药学上可接受的载体（例如水性介质）中，然后优选在施用可引起骨髓损伤的药物的8小时内静脉内施用。在本发明中特别优选的极低剂量不会引起任何显着的副作用。

2. 发明授权

US5294430A Use of dithiocarbamates to treat myelosuppression 失效
标题翻译：使用二硫代氨基甲酸盐治疗骨髓抑制
公开(公告)号：US5294430A
公开(公告)日：1994-03-15
申请号：US922688
申请日：1992-07-30
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27 , A61K38/00 , C07K14/53 , C12N5/077 , A61K39/00
CPC分类号： C07K14/53 , A61K31/27 , A61K38/00 , Y10S514/922 , Y10S514/974
摘要： A process for preventing or ameliorating the myelosuppression which can occur in a mammal such as a human cancer patient being treated with a platinum-free antineoplastic drug is provided, comprising administering an effective dosage of a dithiocarbamate compound to said mammal, preferably subsequent to administration of the cytotoxic drug.
摘要翻译：提供了一种预防或改善可以发生在哺乳动物例如用无铂抗肿瘤药物治疗的人类癌症患者中的骨髓抑制的方法，包括向所述哺乳动物施用有效剂量的二硫代氨基甲酸酯化合物，优选在给予细胞毒性药物。

3. 发明授权

US5169765A Method for stimulating production of bone marrow cell growth factors using dithiocarbamates 失效
标题翻译：使用二硫代氨基甲酸盐刺激骨髓细胞生长因子产生的方法
公开(公告)号：US5169765A
公开(公告)日：1992-12-08
申请号：US586304
申请日：1990-09-21
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27 , A61K38/00 , C07K14/53 , C12N5/077
CPC分类号： C12N5/0669 , A61K31/27 , C07K14/53 , A61K38/00 , C12N2501/999 , Y10S514/823 , Y10S514/885 , Y10S514/922
摘要： A process is provided for obtaining one or more bone marrow cell growth factors having granulocyte/macrophage progenitor cell colony stimulating activity, said process comprising: (a) adding to the culture medium of an in vitro, established bone marrow culture a growth factor-stimulating amount of a dithiocarbamate; (b) separating the said dithiocarbamate from the in vitro treated bone marrow culture, adding fresh culture medium to said in vitro treated bone marrow culture, and permitting the concentration of said growth factor or factors to increase in said fresh culture medium; and (c) isolating said growth factor or factors from said fresh culture medium.
摘要翻译：提供了一种用于获得具有粒细胞/巨噬细胞祖细胞集落刺激活性的一种或多种骨髓细胞生长因子的方法，所述方法包括：（a）向体外培养的骨髓培养物中加入生长因子刺激二硫代氨基甲酸盐的量; （b）从体外处理的骨髓培养物中分离出所述二硫代氨基甲酸盐，向所述体外处理的骨髓培养物中加入新鲜培养基，并允许所述生长因子或因子的浓度在所述新鲜培养基中增加; 和（c）从所述新鲜培养基中分离所述生长因子或因子。

4. 发明授权

US5187193A Method for stimulating transplanted bone marrow cells 失效
标题翻译：刺激移植骨髓细胞的方法
公开(公告)号：US5187193A
公开(公告)日：1993-02-16
申请号：US673089
申请日：1991-03-21
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27
CPC分类号： A61K31/27
摘要： A process is provided for obtaining one or more bone marrow cell growth factors having granulocyte/macrophage progenitor cell colony stimulating activity, said process comprising: (a) adding to the culture medium of an in vitro, established bone marrow culture a growth factor-stimulating amount of a dithiocarbamate; (b) separating the said dithiocarbamate from the in vitro treated bone marrow culture, adding fresh culture medium to said in vitro treated bone marrow culture, and permitting the concentration of said growth factor or factors to increase in said fresh culture medium; and (c) isolating said growth factor or factors from said fresh culture medium.
摘要翻译：提供了一种用于获得具有粒细胞/巨噬细胞祖细胞集落刺激活性的一种或多种骨髓细胞生长因子的方法，所述方法包括：（a）向体外培养的骨髓培养物中加入生长因子刺激二硫代氨基甲酸盐的量; （b）从体外处理的骨髓培养物中分离出所述二硫代氨基甲酸盐，向所述体外处理的骨髓培养物中加入新鲜培养基，并允许所述生长因子或因子的浓度在所述新鲜培养基中增加; 和（c）从所述新鲜培养基中分离所述生长因子或因子。

5. 发明授权

US4938949A Treatment of damaged bone marrow and dosage units therefor 失效
标题翻译：治疗受损骨髓及其剂量单位
公开(公告)号：US4938949A
公开(公告)日：1990-07-03
申请号：US243405
申请日：1988-09-12
申请人： Richard F. Borch , Therese K. Schmalbach
发明人： Richard F. Borch , Therese K. Schmalbach
IPC分类号： A61K31/27 , A61K31/28 , A61K45/06 , A61P7/00 , A61P35/00 , A61P39/02
CPC分类号： A61K31/27 , Y10S514/922
摘要： Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R.sub.1 R.sub.2 NCSSM or R.sub.1 R.sub.2 NCSS--SCSNR.sup.3 R.sup.4, wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R.sup.1 and R.sup.2 and one of R.sup.3 and R.sup.4 can be H, or R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g.
摘要翻译：各种类型的生物处理，包括抗肿瘤药物的抗肿瘤治疗可能会损害骨髓的血液形成功能。至少在某种程度上可以使用有效量（优选极低剂量）的药学上可接受的二硫代氨基甲酸酯化合物，包括式R1R2NCSSM或R1R2NCSS-SCSNR3R4的化合物，其中R 1，R 2，R 3和 R4是相同或不同的未取代或被羟基取代的脂族或脂环族或杂脂肪族基团，或R 1和R 2之一，R 3和R 4中的一个可以是H，或者R 1和R 2或R 3和R 4与N原子一起一对R基团被取代的基团可以是被环氧或第二环氮中断的脂族或脂族的5-或6-元N-杂环，M是H或一当量的药学上可接受的阳离子在这种情况下，分子的其余部分是带负电荷的。哺乳动物的剂量可以为约0.001至30mg / kg体重。对于较大的哺乳动物，包括人类，典型的剂量单位小于10mg / kg，例如 <3 mg / kg。剂量单位可以溶解在合适的药学上可接受的载体（例如水性介质）中，然后优选在施用可引起骨髓损伤的药物的8小时内静脉内施用。在本发明中特别优选的极低剂量不会引起任何显着的副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式